InsiderSignalSign in

← Insider buys

James E Flynn has bought stock on 32 days since Jan 2016

* Director by Deputization, 10% at Larimar Therapeutics, Inc., and 39 other companies

SEC CIK 0001352546 · Filings on SEC.gov ↗

$388.9MBought

$385.4MSold

Mar 2Last buy

James E Flynn's record

3 months after each buy, from the first price a copier could get.

−9.1%Average

−14.9 ptsVs S&P 500

3 of 9Higher

9 buys since 2016 with 3 months of prices.

Companies

Every filing

69 filings since Jan 2016, newest first

Larimar Therapeutics, Inc.

* Director by Deputization, 10%

$25.0M+16.0%Mar 2

Nuvalent, Inc.

Director by Deputization, 10%

$70.9M−4.0%Nov 24

Larimar Therapeutics, Inc.

* Director by Deputization, 10%

$30.0M+44.0%Aug 4

Ars Pharmaceuticals, Inc.

10% owner

$10.1M−5.0%Nov 13

Nuvalent, Inc.

* Director by Deputization, 10%

$195.5M−10.0%Oct 24

Bicara Therapeutics Inc.

Possible Members of 10% Group, 10%

$1.3M+4.0%Sep 17

Adapthealth Corp.

*Possible Member of 10% Group, 10%

$3.8M−3.0%Mar 12

Larimar Therapeutics, Inc.

* Director by Deputization, 10%

$37.5M+25.0%Feb 16

Oncorus, Inc.

Possible Member of 10% Group, 10%

$88K−11.0%Dec 30

Oncorus, Inc.

*Possible Member of 10% Group, 10%

$38K−4.0%Dec 21

Nuvalent, Inc.

Director by Deputization, 10%

$21.8M+3.0%Nov 7

Larimar Therapeutics, Inc.

* Director by Deputization, 10%

$35.0M+191.0%Sep 20

Mirum Pharmaceuticals, Inc.

* Possible Member of 10% Group, 10%

$962K−1.0%Jun 8

Pepgen Inc.

Possible Member of 10% Group, 10%

$5.0M+78.0%May 10

Xilio Therapeutics, Inc.

Possible Member of 10% Group, 10%

$12.4M+51.0%Oct 28

Mirum Pharmaceuticals, Inc.

* Possible Member of 10% Group, 10%

$1.6M−3.0%Jul 13

Mirum Pharmaceuticals, Inc.

* Possible Member of 10% Group, 10%

$1.1M−2.0%Jul 7

Larimar Therapeutics, Inc.

* Director by Deputization, 10%

$6.0M+13.0%Jul 2

Singular Genomics Systems, Inc.

*Possible Member of 10% Group, 10%

$33.0M+20.0%Jun 3

Werewolf Therapeutics, Inc.

Possible Member of 10% Group, 10%

$12.8M+46.0%May 4

Edgewise Therapeutics, Inc.

Possible Member of 10% Group, 10%

$10.0M+19.0%Mar 30

Oncorus, Inc.

*Possible Member of 10% Group, 10%

$5.7M+11.0%Feb 18

Terns Pharmaceuticals, Inc.

Possible Member of 10% Group, 10%

$11.3M+39.0%Feb 9

Lumos Pharma, Inc.

*Possible Member of 10% Group, 10%

$3.4M−16.0%Jan 8

Graybug Vision, Inc.

*Possible Member of 10% Group, 10%

$25.0M+42.0%Oct 1

Acutus Medical, Inc.

Director by Deputization, 10%

$27.0M+53.0%Aug 12

Revolution Medicines, Inc.

Possible Member of 10% Group, 10%

$10.2M+40.0%Feb 18

Schrodinger, Inc.

Possible Member of 10% Group, 10%

$4.3M+19.0%Feb 10

Black Diamond Therapeutics, Inc.

Possible Member of 10% Group, 10%

$7.6M+106.0%Feb 3

Homology Medicines, Inc.

Possible Member of 10% Group, 10%

$8.0M−11.0%Jan 31

Homology Medicines, Inc.

Possible Member of 10% Group, 10%

$10.0M−12.0%Jan 28

Homology Medicines, Inc.

Possible Member of 10% Group, 10%

$7.7M−6.0%Dec 27

Homology Medicines, Inc.

Possible Member of 10% Group, 10%

$3.6M−3.0%Dec 23

Cabaletta Bio, Inc.

Possible Member of 10% Group, 10%

$7.7M+75.0%Oct 30

Frequency Therapeutics, Inc.

Possible Member of 10% Group, 10%

$4.0M+30.0%Oct 7

Aclaris Therapeutics, Inc.

10% owner

$1.9M−15.0%Jul 1

Aclaris Therapeutics, Inc.

10% owner

$2.1M−9.0%Jun 25

Aclaris Therapeutics, Inc.

10% owner

$3.8M−10.0%May 13

Homology Medicines, Inc.

*Director by Deputization, 10%

$12.0M+10.0%Apr 15

Shockwave Medical, Inc.

Possible Member of 10% Group, 10%

$510K+10.0%Mar 11

Arvinas Inc.

Possible Member of a 10% Group, 10%

$5.0M+34.0%Oct 1

Constellation Pharmaceuticals Inc

Possible Member of 10% Group, 10%

$3.0M+31.0%Jul 23

Avadel Pharmaceuticals Plc

*Possible member of 10% group, 10%

$683K−3.0%Jun 25

Mallinckrodt Plc

*Possible member of 10% group, 10%

$4.2M−4.0%May 10

Homology Medicines, Inc.

*Director by Deputization, 10%

$20.0M+31.0%Apr 4

Proteon Therapeutics Inc

*Director by Deputization

$193K+10.0%Dec 4

Rhythm Pharmaceuticals, Inc.

Possible Member of 10% Group, 10%

$6.0M+61.0%Oct 10

Recro Pharma, Inc.

Possible Member of 10% Group, 10%

$706K−5.0%Jun 14

Recro Pharma, Inc.

Possible Member of 10% Group, 10%

$444K−3.0%Jun 9

Ehealth, Inc.

Possible Members of 10% Group, 10%

$5.0M−19.0%Apr 27

About James E Flynn

James E. Flynn is the Managing Partner of Deerfield Management, a leading healthcare-focused investment firm, where he joined in 2000 and assumed leadership in 2005.( Under his direction, Deerfield has expanded into healthcare information via the Deerfield Institute, venture investments, Deerfield Discovery and Development, LLC, the Deerfield Foundation, and a New York City innovation center.( Previously, he was a top-ranked analyst at Furman Selz (ING Barings), Vice President of Corporate Development at Alpharma Inc., and a senior analyst at Kidder, Peabody & Co.(

Flynn serves as Director by Deputization, 10% Owner at Nuvalent, Inc. (NUVL), holding approximately 17 million shares valued over $1.4 billion as of mid-2025, reflecting Deerfield's significant stake.( He holds a BS in Cellular and Molecular Biology and Economics from the University of Michigan and an MS in Biotechnology from Johns Hopkins University, and serves on boards including Mount Sinai Health System and as Chairman of the New York Academy of Medicine.(

Written by Perplexity from public sources.

Filings come from SEC EDGAR. Not investment advice.